

Silvia Pomella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5749359/publications.pdf>

Version: 2024-02-01

33
papers

845
citations

687363

13
h-index

642732

23
g-index

37
all docs

37
docs citations

37
times ranked

1489
citing authors

#	ARTICLE	IF	CITATIONS
1	PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. <i>Cancer Discovery</i> , 2017, 7, 884-899.	9.4	221
2	Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma. <i>Nature Genetics</i> , 2019, 51, 1714-1722.	21.4	113
3	Chemical genomics reveals histone deacetylases are required for core regulatory transcription. <i>Nature Communications</i> , 2019, 10, 3004.	12.8	107
4	Dose-dependent activation of gene expression is achieved using CRISPR and small molecules that recruit endogenous chromatin machinery. <i>Nature Biotechnology</i> , 2020, 38, 50-55.	17.5	51
5	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 977-983.	2.8	49
6	MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma. <i>Clinical Epigenetics</i> , 2015, 7, 82.	4.1	33
7	Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma. <i>Nature Communications</i> , 2021, 12, 192.	12.8	33
8	In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 125.	17.0	28
9	Miswired Enhancer Logic Drives a Cancer of the Muscle Lineage. <i>iScience</i> , 2020, 23, 101103.	4.1	26
10	Epigenetic remodelling in human hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 107.	8.6	21
11	CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas. <i>Frontiers in Pharmacology</i> , 2020, 11, 1230.	3.5	20
12	New Insights on the Nuclear Functions and Targeting of FAK in Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1998.	4.1	19
13	DNMT3A and DNMT3B Targeting as an Effective Radiosensitizing Strategy in Embryonal Rhabdomyosarcoma. <i>Cells</i> , 2021, 10, 2956.	4.1	18
14	Small heat-shock protein HSPB3 promotes myogenesis by regulating the lamin B receptor. <i>Cell Death and Disease</i> , 2021, 12, 452.	6.3	16
15	Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 364.	8.6	15
16	Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models. <i>European Journal of Medicinal Chemistry</i> , 2022, 237, 114410.	5.5	15
17	MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10671.	4.1	14
18	Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype. <i>International Journal of Radiation Biology</i> , 2021, 97, 943-957.	1.8	13

#	ARTICLE	IF	CITATIONS
19	SNAI2-Mediated Repression of <i>BIM</i> Protects Rhabdomyosarcoma from Ionizing Radiation. <i>Cancer Research</i> , 2021, 81, 5451-5463.	0.9	13
20	FAK Signaling in Rhabdomyosarcoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8422.	4.1	8
21	MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression. <i>Frontiers in Oncology</i> , 2022, 12, 835642.	2.8	5
22	The CRISP(Y) Future of Pediatric Soft Tissue Sarcomas. <i>Frontiers in Chemistry</i> , 2020, 8, 178.	3.6	3
23	Notch Signaling in Pediatric Soft Tissue Sarcoma. , 2018, , 277-312.		1
24	Abstract A08: Development of FGFR4-specific chimeric antibody receptor (CAR) T cell and bispecific T cell engager (BiTE) for rhabdomyosarcoma (RMS) immunotherapy. , 2020, , .		1
25	The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). <i>Blood</i> , 2011, 118, 76-76.	1.4	1
26	Abstract 47: Identification of first-in-class KDM3B inhibitors that suppress PAX3-FOXO1 oncogene activity in fusion positive rhabdomyosarcoma. , 2021, , .		0
27	ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112. <i>Blood</i> , 2011, 118, 2574-2574.	1.4	0
28	Abstract 1772: Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL). , 2012, , .		0
29	Abstract 1922: miR-301 expression is deregulated in rhabdomyosarcoma. <i>Cancer Research</i> , 2016, 76, 1922-1922.	0.9	0
30	Abstract 2065: Targeting the crosstalk between MET and Notch signaling in Rhabdomyosarcoma. , 2017, , .		0
31	Abstract 4139: SNAI2 inhibition promotes myogenic differentiation and prevents tumorigenic features of embryonal rhabdomyosarcoma. , 2018, , .		0
32	Abstract 4175: Identification of novel inhibitors of the PAX3-FOXO1 fusion oncogene in rhabdomyosarcoma. , 2020, , .		0
33	Abstract B35: Liaison between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in fusion-negative rhabdomyosarcoma. , 2020, , .		0